Market closedNon-fractional
Caribou Biosciences/CRBU
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Caribou Biosciences
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
Ticker
CRBU
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Berkeley, United States
Employees
158
Website
cariboubio.com
CRBU Metrics
BasicAdvanced
$220M
Market cap
-
P/E ratio
-$1.43
EPS
2.56
Beta
-
Dividend rate
Price and volume
Market cap
$220M
Beta
2.56
Financial strength
Current ratio
10.493
Quick ratio
10.255
Long term debt to equity
7.543
Total debt to equity
7.911
Management effectiveness
Return on assets (TTM)
-21.70%
Return on equity (TTM)
-37.09%
Valuation
Price to revenue (TTM)
5.905
Price to book
0.64
Price to tangible book (TTM)
0.64
Price to free cash flow (TTM)
-1.714
Growth
Revenue change (TTM)
127.41%
Earnings per share change (TTM)
-19.80%
3-year revenue growth (CAGR)
39.72%
3-year earnings per share growth (CAGR)
-30.64%
What the Analysts think about CRBU
Analyst Ratings
Majority rating from 9 analysts.
CRBU Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$2.4M
-31.43%
Net income
-$41M
19.42%
Profit margin
-1,716.66%
74.15%
CRBU Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.48
-$0.12
-$0.39
-$0.46
-
Expected
-$0.49
-$0.42
-$0.37
-$0.40
-$0.46
Surprise
-3.00%
-71.17%
6.10%
16.16%
-
CRBU News
AllArticlesVideos
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU
GlobeNewsWire·5 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU
PRNewsWire·2 days ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU
Accesswire·3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Caribou Biosciences stock?
Caribou Biosciences (CRBU) has a market cap of $220M as of July 27, 2024.
What is the P/E ratio for Caribou Biosciences stock?
The price to earnings (P/E) ratio for Caribou Biosciences (CRBU) stock is 0 as of July 27, 2024.
Does Caribou Biosciences stock pay dividends?
No, Caribou Biosciences (CRBU) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Caribou Biosciences dividend payment date?
Caribou Biosciences (CRBU) stock does not pay dividends to its shareholders.
What is the beta indicator for Caribou Biosciences?
Caribou Biosciences (CRBU) has a beta rating of 2.56. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Caribou Biosciences stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.